Fezakinumab

Fezakinumab
Monoclonal antibody
Type	Whole antibody
Target	IL-22
Clinical data
ATC code	none;
Identifiers
CAS Number	1007106-86-6 ;
ChemSpider	none;
UNII	0S77U25XZ3;
KEGG	D09615;
Chemical and physical data
Formula	C6408H9873N1706O2016S44
Molar mass	143.87 kg/mol
(what is this?) (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,^[1] designed for the treatment of psoriasis and rheumatoid arthritis.^[2]

Research and development

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,^[3] but data was not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.^[4]

References

↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
↑ "Archived copy" (PDF). Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.
↑ "Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07.
↑ Richardson, Brian. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.

javascript:void(0);

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.

[2] "Archived copy" (PDF). Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.

[3] "Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07.

[4] Richardson, Brian. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.